Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Larazotide acetate reduces symptoms in celiac patients undergoing a gluten challenge

A study published ahead of print in the Alimentary Pharmacology & Therapeutics examines larazotide acetate in patients with celiac disease undergoing a gluten challenge.

News image

Celiac disease, an autoimmune disorder triggered by gluten ingestion, is managed by a gluten-free diet, which is difficult for many patients.

Larazotide acetate is a first-in-class oral peptide that prevents tight junction opening, and may reduce gluten uptake and associated sequelae.
 
Dr Kelly and colleagues from Massachussetts, USA evaluated the efficacy and tolerability of larazotide acetate during gluten challenge.
 
The research team performed an exploratory, double-blind, randomized, placebo-controlled study including 184 patients who maintained a gluten-free diet before and during the study.

After a gluten-free diet run-in, patients were randomized to larazotide acetate or placebo, and received 2.7 grams of gluten daily for 6 weeks.

Larazotide acetate 1-mg limited gluten-induced symptoms
Alimentary Pharmacology & Therapeutics

The researchers' outcomes included an experimental biomarker of intestinal permeability, the lactulose-to-mannitol ratio and clinical symptoms assessed by Gastrointestinal Symptom Rating Scale, and anti-transglutaminase antibody levels.
 
The research team observed no significant differences in lactulose-to-mannitol ratios between larazotide acetate and placebo groups.

Larazotide acetate 1-mg limited gluten-induced symptoms measured by Gastrointestinal Symptom Rating Scale.

Mean ratio of anti-tissue transglutaminase IgA levels over baseline was 19 in the placebo group compared with 6, 4 and 8 in the larazotide acetate 1-, 4-, and 8-mg groups, respectively.

The team found that the adverse event rates were similar between larazotide acetate and placebo groups.
 
Dr Kelly and colleagues commented, "Larazotide acetate reduced gluten-induced immune reactivity and symptoms in patients with celiac disease undergoing gluten challenge and was generally well tolerated."

"However, no significant difference in lactulose-to-mannitol ratios between larazotide acetate and placebo was observed."

"Results and design of this exploratory study can inform the design of future studies of pharmacological interventions in patients with celiac disease."

Aliment Pharmacol Ther 2012: DOI: 10.1111/apt.12147
28 November 2012

Go to top of page Email this page Email this page to a colleague

 23 September 2014

Advanced search
 23 September 2014 
Recurrence of Barrett's neoplasia after resection
 23 September 2014 
Abnormal prion protein in appendixes
 23 September 2014 
Upper GI bleeding with drug combinations
 22 September 2014 
Anorectal function after low anterior resection
 22 September 2014 

Anorectal stricture in Crohn's

 22 September 2014 
Malignancies in celiac disease
 19 September 2014 
Adhesions in abdominal and pelvic surgery
 19 September 2014 
Repeat colonoscopy among US Medicare
 19 September 2014 
Progression to liver cancer in HCV-infected Veterans
 18 September 2014 
Patient improvement following sacral neuromodulation
 18 September 2014 
Autoimmune diseases in functional gastrointestinal disorders
 18 September 2014 
New diagnostic score for hepatic steatosis
 17 September 2014 
Orange juice intake for bowel preparation
 17 September 2014 
Treatment of fistulising perianal Crohn's disease
 17 September 2014 
Interval colorectal cancers
 16 September 2014 
Fiber treats IBS
 16 September 2014 
Resected biliary tract cancer
 16 September 2014 
Postoperative adhesions in digestive surgery
 15 September 2014 
Fecal transplantation for C.diff infection
 15 September 2014 
Prunes and GI function
 15 September 2014 
Antidepressants for IBS
 12 September 2014 
Metabolic syndrome delays HBeAg seroclearance
 12 September 2014 
Drug-induced liver disease
 12 September 2014 
Management of complex colon polyps
 11 September 2014 
Hepatobiliary cirrhosis risk after organ transplant
 11 September 2014 
Sofosbuvir plus peginterferon/ribavirin for HCV
 11 September 2014 
Patient perceptions in celiac disease
 10 September 2014 
Adhesions in abdominal and pelvic surgery
 10 September 2014 
Acute kidney injury after colonoscopy
 10 September 2014 
Management algorithm for endoscopic mucosal resection of colonic lesions
 09 September 2014 
PPIs and spontaneous bacterial peritonitis in cirrhosis
 09 September 2014 
Neutrophil function and mortality in cirrhosis
 09 September 2014 
MELD and liver cancer survival
 08 September 2014 
Vagal nerve blockade and morbid obesity
 08 September 2014 
Comparison of diet programs in overweight and obese adults
 08 September 2014 
Long-term follow-up after bariatric surgery
 05 September 2014 
Healing rates in reflux esophagitis
 05 September 2014 
Progression of environmental enteropathy
 05 September 2014 
Diabetes and liver transplant outcomes
 04 September 2014 
Colectomy rates for refractory ulcerative colitis
 04 September 2014 
Infliximab prevents long-term Crohn’s disease recurrence
 04 September 2014 
Histological recovery with gluten-free diet in celiac disease
 03 September 2014 
Predictors of response in Crohn's disease
 03 September 2014 
Diagnosis of atrophic gastritis
 03 September 2014 
Safety of reinitiation of infliximab therapy
 02 September 2014 
SSRIs and depression in Hep C
 02 September 2014 
Bariatric surgery for obesity
 02 September 2014 
Eosinophilic esophagitis in adults
 01 September 2014 
Risks with anti-TNF in pediatric IBD
 01 September 2014 
Fecal hemoglobin and colorectal cancer screening
 01 September 2014 
Genetic variants in alcoholic liver disease
 29 August 2014 
Gluten-free diet for asymptomatic celiac disease
 29 August 2014 
NSAID-induced small intestinal injury and diaphragm disease
 29 August 2014 
Symptom evaluation in functional dyspepsia
 28 August 2014 
Detection of gastroesophageal reflux symptoms
 28 August 2014 
Colorectal-cancer mortality after adenoma removal
 28 August 2014 
Predictoris of C. diff in out-patients
 27 August 2014 
Endoscopy outcomes in community hospital vs tertiary academic centers
 27 August 2014 
UV exposure and IBD hospitalizations
 27 August 2014 
Hepatocellular carcinoma screening in liver disease

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us